124 related articles for article (PubMed ID: 29717829)
1. [Expressions of ERK and p-ERK in advanced prostate cancer].
Han J; Zhang P; Zheng L; Zhang Y; Wang KN; Fan LM; Xie HD; Wang SR; Zhang ZW; Wang QF; Jiang T
Zhonghua Nan Ke Xue; 2017 May; 23(5):406-411. PubMed ID: 29717829
[TBL] [Abstract][Full Text] [Related]
2. [Expressions of JNK and p-JNK in advanced prostate cancer and their clinical implications].
Zhang P; Han J; Zheng L; Wang KN; Fan LM; Xie HD; Wang SR; Jiang T
Zhonghua Nan Ke Xue; 2017 Apr; 23(4):309-314. PubMed ID: 29714414
[TBL] [Abstract][Full Text] [Related]
3. [Expressions of E-cadherin and alpha-catenin in benign, malignant and metastatic prostate tumors].
Jiang T; Jiang H; Su XM; Zheng L; Li QL; Zhang ZW; Li XC
Zhonghua Nan Ke Xue; 2012 Jun; 18(6):499-503. PubMed ID: 22774602
[TBL] [Abstract][Full Text] [Related]
4. Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5α-reductase and extracellular signal-regulated kinase.
Youn DH; Park J; Kim HL; Jung Y; Kang J; Jeong MY; Sethi G; Seok Ahn K; Um JY
Oncotarget; 2017 Feb; 8(6):9500-9512. PubMed ID: 27880726
[TBL] [Abstract][Full Text] [Related]
5. Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.
Huang L; Li M; Wang D; He J; Wu W; Zeng Q; Li J; Xiao M; Hu J; He Y; Li Y; Mai L; Liu W
Hum Pathol; 2016 Jan; 47(1):109-14. PubMed ID: 26546252
[TBL] [Abstract][Full Text] [Related]
6. miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition.
Zhao Z; Zhao S; Luo L; Xiang Q; Zhu Z; Wang J; Liu Y; Luo J
Br J Cancer; 2021 Mar; 124(5):982-994. PubMed ID: 33239676
[TBL] [Abstract][Full Text] [Related]
7. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL.
Chang CC; Lee YC; Tsai HW; Yii SC; Yen TH; Chu FY
Asian Pac J Cancer Prev; 2015; 16(13):5261-4. PubMed ID: 26225663
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphatase.
Gesmundo I; Di Blasio L; Banfi D; Villanova T; Fanciulli A; Favaro E; Gamba G; Musuraca C; Rapa I; Volante M; Munegato S; Papotti M; Gontero P; Primo L; Ghigo E; Granata R
Cancer Lett; 2019 May; 449():252-262. PubMed ID: 30790678
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of secreted group IIA phospholipase A(2) in benign prostatic hyperplasia and prostate cancer: a biomarker for inflammation or neoplasia?
Menschikowski M; Hagelgans A; Fuessel S; Mareninova OA; Neumeister V; Wirth MP; Siegert G
Inflammation; 2012 Jun; 35(3):1113-8. PubMed ID: 22189868
[TBL] [Abstract][Full Text] [Related]
13.
Kim YH; Byun YJ; Kim WT; Jeong P; Yan C; Kang HW; Kim YJ; Lee SC; Moon SK; Choi YH; Yun SJ; Kim WJ
J Korean Med Sci; 2018 Nov; 33(47):e303. PubMed ID: 30450027
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
15. A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer.
Alaoui-Jamali MA; Bismar TA; Gupta A; Szarek WA; Su J; Song W; Xu Y; Xu B; Liu G; Vlahakis JZ; Roman G; Jiao J; Schipper HM
Cancer Res; 2009 Oct; 69(20):8017-24. PubMed ID: 19808972
[TBL] [Abstract][Full Text] [Related]
16. Expression of livin, survivin and caspase-3 in prostatic cancer and their clinical significance.
Gu J; Ren L; Wang X; Qu C; Zhang Y
Int J Clin Exp Pathol; 2015; 8(11):14034-9. PubMed ID: 26823716
[TBL] [Abstract][Full Text] [Related]
17. Caspase-3/CPP32 immunoreactivity and its correlation with frequency of apoptotic bodies in human prostatic carcinomas and benign nodular hyperplasias.
Sohn JH; Kim DH; Choi NG; Park YE; Ro JY
Histopathology; 2000 Dec; 37(6):555-60. PubMed ID: 11122438
[TBL] [Abstract][Full Text] [Related]
18. Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma.
Chen Y; Lin Y; Nie P; Jiang W; Liu Y; Yuan R; Li M; Zhao S; Lin H; Li P; Zhang J; Hu Z; Xu J; Zhu X
Med Sci Monit; 2017 Apr; 23():1768-1774. PubMed ID: 28400549
[TBL] [Abstract][Full Text] [Related]
19. [Correlation of FOXA1 with the malignancy and progression of prostate cancer].
Feng W; Zhang HB; Wang YM; Hu JL
Zhonghua Nan Ke Xue; 2015 May; 21(5):414-9. PubMed ID: 26117938
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and prostate cancer: correlation with Gleason score.
Correa LL; Neto LV; Lima GA; Gabrich R; Miranda LC; Gadelha MR
Int Braz J Urol; 2015; 41(1):110-5. PubMed ID: 25928516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
